Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.

Serie, Daniel J; Crook, Julia E; Necela, Brian M; Dockter, Travis J; Wang, Xue; Asmann, Yan W; Fairweather, DeLisa; Bruno, Katelyn A; Colon-Otero, Gerardo; Perez, Edith A; Thompson, E Aubrey; Norton, Nadine

Serie, Daniel J; Crook, Julia E; Necela, Brian M; Dockter, Travis J; Wang, Xue; Asmann, Yan W; Fairweather, DeLisa; Bruno, Katelyn A; Colon-Otero, Gerardo; Perez, Edith A; Thompson, E Aubrey; Norton, Nadine.

Affiliation

Serie DJ; aHealth Sciences Research Departments of bCancer Biology cCardiovascular Diseases dHematology/Oncology, Mayo Clinic, Jacksonville, Florida eHealth Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.

Pharmacogenet Genomics ; 27(10): 378-385, 2017 Oct.

Article in En | MEDLINE | ID: mdl-28763429

Subject(s)

Antineoplastic Agents, Immunological/toxicity; Breast Neoplasms/drug therapy; Genome-Wide Association Study; Heart/drug effects; Trastuzumab/toxicity; Breast Neoplasms/pathology; Female; Humans; Receptor, ErbB-2/antagonists & inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Genome-Wide Association Study / Trastuzumab / Antineoplastic Agents, Immunological / Heart Type of study: Risk_factors_studies Limits: Female / Humans Language: En Year: 2017 Type: Article

Fulltext

XML

PubMed Links

Search on Google